Joyce Meghan V. 4
4 · Guardant Health, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Guardant Health (GH) Director Meghan V. Joyce Sells Shares, Exercises Options
What Happened
Meghan V. Joyce, a director of Guardant Health (GH), exercised 10,000 stock options on 2026-06-03 and sold the resulting 10,000 shares that same day in multiple open-market trades. She exercised 1,197 options at $38.42 (cost $45,989) and 8,803 options at $38.01 (cost $334,558), for a total exercise cost of about $380,547. The subsequent open-market sales were 3,516 shares at a weighted avg ~$126.52 ($444,829), 5,728 shares at ~$127.11 ($728,060), 650 shares at ~$128.02 ($83,213), and 106 shares at ~$129.31 ($13,707), for total gross proceeds of approximately $1,269,809.
Key Details
- Transaction date: all activity reported for 2026-06-03; Form 4 filed 2026-06-04 (no late filing indicated).
- Exercise details: 10,000 options exercised (codes M), total exercise cost ≈ $380,547.
- Sales: 10,000 shares sold in multiple open-market trades (codes S), total proceeds ≈ $1,269,809; weighted sale prices spread across $125.80–$129.83 (see footnotes F1–F4 for ranges).
- Net cash from the sequence (proceeds minus exercise cost) ≈ $889,262.
- Shares owned after transaction: not specified in the provided filing extract.
- Footnotes: F1–F4 note the sales were in multiple trades at specified price ranges; F5 and F6 note the underlying option awards vested in full on June 14, 2023 and June 12, 2024 respectively. The filing includes $0 "Disposed" derivative lines reflecting the exercise/conversion reporting mechanics.
Context
- This was an option exercise followed by same-day open-market sales of the acquired shares (common practice to cover exercise cost and taxes). The SEC code M denotes option exercise; S denotes open-market sale.
- Sales by insiders are routine and do not, by themselves, indicate whether they view the company more or less favorably. Purchases tend to be a stronger signal of insider conviction.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-06-03$38.42/sh+1,197$45,989→ 12,380 total - Exercise/Conversion
Common Stock
2026-06-03$38.01/sh+8,803$334,558→ 21,183 total - Sale
Common Stock
[F1]2026-06-03$126.52/sh−3,516$444,829→ 17,667 total - Sale
Common Stock
[F2]2026-06-03$127.11/sh−5,728$728,060→ 11,939 total - Sale
Common Stock
[F3]2026-06-03$128.02/sh−650$83,213→ 11,289 total - Sale
Common Stock
[F4]2026-06-03$129.31/sh−106$13,707→ 11,183 total - Exercise/Conversion
Stock Option (Right to Buy)
[F5]2026-06-03−1,197→ 7,908 totalExercise: $38.42Exp: 2032-06-14→ Common Stock (1,197 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F6]2026-06-03−8,803→ 0 totalExercise: $38.01Exp: 2033-06-14→ Common Stock (8,803 underlying)
Footnotes (6)
- [F1]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.785. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $126.815 to $127.75. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $127.92 to $128.24. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.28 to $129.83. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The stock option award vested in full on June 14, 2023.
- [F6]The stock option award vested in full on June 12, 2024.